New treatments and shifting paradigms in differentiated thyroid cancer management.

@article{Carter2011NewTA,
  title={New treatments and shifting paradigms in differentiated thyroid cancer management.},
  author={W. Bradford Carter and John B. Tourtelot and Jason G Savell and Howard S. Lilienfeld},
  journal={Cancer control : journal of the Moffitt Cancer Center},
  year={2011},
  volume={18 2},
  pages={96-103}
}
BACKGROUND Although most thyroid cancer patients have an excellent prognosis, 10% of low-risk cancers and 25% of high-risk cancers recur, with mortality rates in excess of 50% at 3 years for aggressive thyroid cancer. Traditional paradigms including surgery, I¹³¹ ablation, and TSH suppression do not offer additional therapeutic options for cancers that fail these interventions. Risk stratification and outcomes data are shifting the treatment paradigms to favor more individualized therapies… CONTINUE READING